Hudson Bay Capital Management
BCAX

Hudson Bay Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Hudson Bay Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Sell
105,000
-128,703
-55% -$2.87M 0.01% 699
2026
Q1 		$4.65M Buy
233,703
+83,703
+56% +$1.44M 0.02% 533
2025
Q4 		$2.52M Buy
+150,000
New +$2.56M 0.01% 666

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hudson Bay Capital Management's BCAX Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Bicara Therapeutics (BCAX) stake by 55% in Q2 2026, selling an estimated $2.87M and leaving 105,000 shares worth $3.12M. The position accounts for 0.01% of the portfolio, ranked #699.

Hudson Bay Capital Management first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.65M in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Hudson Bay Capital Management held 105,000 shares of Bicara Therapeutics worth $3.12M as of Q2 2026.
  • Hudson Bay Capital Management sold 128,703 Bicara Therapeutics shares in Q2 2026, an estimated $2.87M.
  • Bicara Therapeutics made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #699 holding.
  • Hudson Bay Capital Management first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Bicara Therapeutics position peaked at $4.65M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.